Healthcare
Immutep Limited(PRRUF)
Live Price
Offline$0.05
+0.00% today
1Y Change
-73.68%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $90.00M
- Revenue Growth
- +31.3%
- EPS Growth
- -18.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immutep Limited (PRRUF) is a Healthcare stock with a market cap of $90.00M and listed on OTC. The stock last traded around $0.05 and down 73.7% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +31.3%, EPS growth of -18.5%, a dividend yield of 0.0%. What stands out right now is revenue +31.3%, EPS -18.5%, free cash flow -73.7% with operating margin -2052.2% and ROIC -122.1%. Valuation already assumes a fairly strong business story at price/sales 15.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRRUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+31.3% vs +7.6% peer median
Operating Margin
Below sector median
-2052.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 24, 2026 with an EPS surprise of -7.0% and a revenue surprise of -42.4%.
The operating picture looks softer than before
Revenue is at +31.3% and EPS is at -18.5%, with operating margin around -2052.2%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | -7.0% | +0.0% | +0.0% | -84.0% |
2025 Aug 4, 2025 | +53.2% | +0.0% | +0.0% | +0.0% |
2025 Feb 26, 2025 | +28.4% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRRUF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRRUF Max Drawdown
-87.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRRUF and SPY.
Company Overview
Immutep Limited
Other OTC
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
- Leadership
- Marc Voigt
- IPO Date
- Feb 22, 2012
- Employees
- 51
- Street Address
- Australia Square
- Mailing
- Sydney, NSW, 2000
- Region
- Sydney, NSW, AU
- Reporting Currency
- USD
- Investor Line
- 61 2 8315 7003
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 15.0
- Price/Book
- 0.9
Growth
- Revenue
- +31.3%
- EPS
- -18.5%
- Free Cash Flow
- -73.7%
Profitability
- Gross Margin
- -522.6%
- Operating Margin
- -2052.2%
- Net Margin
- -1404.1%
- ROE
- -69.2%
- ROIC
- -122.1%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.